Rituximab in cryoglobulinemic vasculitis: First- or second-line therapy?

HCV Infection and Cryoglobulinemia

Volumn 9788847017054, Issue , 2012, Pages 307-313

  Lamprecht, Peter ^a   Klenerman, Paul ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883659101     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-88-470-1705-4_39     Document Type: Chapter

References (39)

1. Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187-192
2. Ferri C, Mascia MT (2006) Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18:54-63
3. Giordano TP, Henderson L, Landgren O et al (2007) Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 297:2010-2017
4. de Sanjose S, Benavente Y, Vajdic CM et al (2008) Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 6:451-458
5. Saadoun D, Sellam J, Ghillani-Dalbin P et al (2006) Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 166:2101-2108
6. Sansonno D, Lauletta G, De Re V et al (2004) Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 34:126-136
7. Quartuccio L, Fabris M, Salvin S et al (2007) Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis. Rheumatology (Oxford) 46:1657-1661
8. Pileri P, Uematsu Y, Campagnoli S et al (1998) Binding of hepatitis C virus to CD81. Science 282:938-941
9. Carbonari M, Caprini E, Tedesco T et al (2005) Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: A model of infection-driven lymphomagenesis. J Immunol 174:6532-6539
10. Charles ED, Green RM, Marukian S et al (2008) Clonal expansion of immunoglobulin M+CD27+ B cells in HCVassociated mixed cryoglobulinemia. Blood 111:1344-1356
11. Landau DA, Rosenzwajg M, Saadoun D et al (2009) The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Ann Rheum Dis 68:337-344
12. Zignego AL, Ferri C, Giannelli F et al (2002) Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 137:571-580
13. Saadoun D, Rosenzwajg M, Landau D et al (2008) Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 111:5334-5341
14. Sansonno D, De Re V, Lauletta G et al (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818-3826
15. Klenerman P, Hill A (2005) T cells and viral persistence: lessons from diverse infections. Nat Immunol 6:873-879
16. Rushbrook SM, Ward SM, Unitt E et al (2005) Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 79:7852-7859
17. Ward SM, Fox BC, Brown PJ et al (2007) Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol 47:316-324
18. Machida K, Tsukiyama-Kohara K, Sekiguch S et al (2009) Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins. Gastroenterology 137:285-296
19. Fortunato G, Calcagno G, Bresciamorra V et al (2008) Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 28:141-152
20. Neumann AU, Lam NP, Dahari H et al (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107
21. Sansonno D, Tucci FA, Troiani L et al (2008) Current and emerging therapeutic approaches in HCV-related mixed cryoglobulinemia. Curr Med Chem 15:117-126
22. Saadoun D, Delluc A, Piette JC, Cacoub P (2008) Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 20:23-28
23. Schröder C, Azimzadeh AM, Wu G et al (2003) Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 12:19-28
24. Zaja F, De Vita S, Mazzaro C et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827-3834
25. Roccatello D, Baldovino S, Rossi D et al (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19:3054-3061
26. Quartuccio L, Soardo G, Romano G et al (2006) Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 45:842-846
27. Koukoulaki M, Abeygunasekara SC, Smith KG, Jayne DR (2005) Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant 20:213-216
28. Pereira AA, Jacobson IM (2009) New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol 6: 403-411
29. Landau DA, Saadoun D, Halfon P et al (2008) Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 58:604-611
30. Casato M, Mecucci C, Agnello V et al (2002) Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood 99: 2259-2261
31. Lamprecht P, Lerin-Lozano C, Merz H et al (2003) Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62:1230-1233
32. Saadoun D, Resche-Rigon M, Sene D et al (2008) Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 67:1431-1436
33. Terrier B, Saadoun D, Sène D et al (2009) Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup study of thirty-two patients. Arthritis Rheum 60:2531-2540
34. Sène D, Ghillani-Dalbin P, Amoura Z et al (2009) Rituximab may form a complex with iGmkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 60:3848-3855
35. Webster DP, Klenerman P, Collier J, Jeffery KJM (2009) Development of novel treatments for hepatitis C. Lancet Infect Dis 9:108-117
36. McHutchison JG, Everson GT, Gordon SC et al (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360:1827-1838
37. Hézode C, Forestier N, Dusheiko G (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360:1839-1850
38. Hoofnagle JH (2009) A step forward in therapy for hepatitis C. N Engl J Med 360:1899-1901
39. Casato M, Lagana B, Pucillo LP, Quinti I (1998) Interferon for hepatitis C virus-negative type II mixed cryoglobulinemia. N Engl J Med 338:1386-1387